marie louise von franz psychotherapy .pdf

MARIE LOUISE VON FRANZ PSYCHOTHERAPY .PDF TRIAL

Above all, in such institutions as these, I say, we must teach that no truth obtained by such means has the moral right to exist” (1897/1983, ♡38. In institutions which offer training in physiology, the moral judgment of students is deliberately impaired by their involvement in disgraceful, barbarous experiments, by a cruel torture of animals which is a mockery of all human decency. (1897/1983, ♦8)Īfter a strongly polemical attack on materialism in general, Jung then continues by asserting that we should start a “revolution” on the part of our leading minds “by forcing morality on science and its exponents. God and the other world are the sole goal of all our philosophical investigations, and if the concepts of God and the other world had nothing to do with morality they would be worthless. All metaphysical speculation is directed to this end. It is the holy and inviolable thing that we must protect, and it is also the reason and purpose of all our speculation and inquiries. In one of them, he quoted Kant who wrote: When he was a twenty-one to twenty-three-year-old student, Jung gave four lectures to his co-students in the fraternity Zofingia in Basel. L ECTURE, K ÜSNACHT, N OVEMby Marie-Louise von Franz Jung’s Rehabilitation of the Feeling Function in Our Civilization

Jung’s Rehabilitation of the Feeling Function in Our CivilizationĬ.G. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Lewis EJ, Hunsicker LG, Clarke WR, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Webster AC, Nagler EV, Morton RL, Masson P. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. (Funded by Boehringer Ingelheim and others EMPA-KIDNEY number, NCT03594110 EudraCT number, 2017-002971-24.).Ĭopyright © 2022 Massachusetts Medical Society.įox CS, Matsushita K, Woodward M, et al. The rates of serious adverse events were similar in the two groups.Īmong a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86 95% CI, 0.78 to 0.95 P = 0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72 95% confidence interval, 0.64 to 0.82 P<0.001). The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to <10 ml per minute per 1.73 m 2, a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.Ī total of 6609 patients underwent randomization. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m 2 of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m 2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200.

MARIE LOUISE VON FRANZ PSYCHOTHERAPY .PDF TRIAL

The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood.

Marie louise von franz psychotherapy .pdf